Skip to content
Clinical Trials – home

Universitaetsklinikum Regensburg AöR

Verified siteinfo

Germany Franz-Josef-Strauss-Allee 11, Grass-Oberisling, 93053 Regensburg, Germany

  • 122 trials recruiting
  • Non-small cell lung cancer · Acute myeloid leukaemia · Pulmonary arterial hypertension
  • Adults and children

About Specializations

Universitaetsklinikum Regensburg AöR in Regensburg, Germany specialises in clinical trials of conditions such as Non-small cell lung cancer, Acute myeloid leukaemia, Pulmonary arterial hypertension, Plasma cell myeloma, and other specialisations. This site conducts important research.

Main research areas of the site

Ophthalmology and Vision Research

At Universitaetsklinikum Regensburg AöR, clinical trials in Eye Diseases focus on urgent vision-threatening conditions such as acute central retinal artery occlusion. The research aims to improve recovery of sight and to test more effective approaches for restoring visual function after sudden retinal injury.

  • Recovery of vision in acute retinal artery occlusion
  • Functional improvement measured through visual acuity outcomes
  • Testing new strategies to protect or restore eyesight

These studies reflect a strong interest in faster diagnosis and better treatment options for patients facing sudden loss of vision.

Oncology and Immunotherapy

The site conducts a broad range of trials in Neoplasms, including melanoma, solid tumors, non-small cell lung cancer, gastroesophageal adenocarcinoma, and head and neck cancers. Many of these studies evaluate immunotherapy combinations and other targeted treatments to improve tumor control, delay recurrence, and extend survival.

  • Melanoma and metastatic melanoma
  • Locally advanced or metastatic non-small cell lung cancer
  • Head and neck squamous cell carcinoma
  • Advanced gastroesophageal adenocarcinoma

The oncology portfolio includes both treatment innovation and post-surgery recurrence prevention, showing a clear focus on more personalized cancer care.

Hematology and Pediatric Blood Cancers

Research in immune system diseases and neoplasms includes trials for acute myeloid leukemia, myelodysplastic syndromes, classical Hodgkin lymphoma, and aggressive B-cell lymphoma in children and adolescents. These studies are designed to refine treatment effectiveness, preserve event-free survival, and support immune recovery while reducing treatment burden where possible.

  • Acute myeloid leukemia and related myelodysplastic syndromes
  • Classical Hodgkin lymphoma
  • Pediatric mature aggressive B-cell lymphoma and leukemia
  • Evaluating optimized chemotherapy and immunotherapy combinations

This area highlights the clinic’s role in advancing both adult and pediatric blood cancer research.

Cardiovascular and Acute Care Studies

Trials in Cardiovascular Diseases address high-risk conditions such as acute myocardial infarction. The main purpose is to improve early treatment and reduce the risk of recurrent cardiac events through better use of anti-thrombotic and emergency therapies.

  • Acute myocardial infarction
  • Preventing repeat cardiac events
  • Evaluating rapid self-administered treatment approaches

These studies emphasize timely intervention in life-threatening cardiovascular emergencies.

Transplant Medicine and Immune Rejection

Research involving immune system processes includes studies in kidney transplant recipients focused on prophylaxis of transplant rejection. The goal is to compare treatment options that may improve drug exposure and support long-term graft protection after transplantation.

  • Kidney transplant recipients
  • Prevention of transplant rejection
  • Comparing oral immunosuppressive treatment performance

These trials contribute to safer and more reliable post-transplant care.

Inflammation and Skin Disease Research

The site also studies skin and connective tissue diseases, especially hidradenitis suppurativa. This work evaluates whether newer anti-inflammatory treatments can better control symptoms in people with moderate to severe disease who have not responded adequately to prior therapy.

  • Hidradenitis suppurativa
  • Chronic inflammatory skin disease management
  • Assessing treatment effectiveness and tolerability

Overall, the research aims to improve symptom control and quality of life for patients with difficult-to-treat inflammatory skin conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Franz-Josef-Strauss-Allee 11, Grass-Oberisling93053 RegensburgGermany
Recruiting now
122 trials
Conditions studied
178
Partner status
Verified site

More sites in RegensburgGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

272 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Medical University Of Graz

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:AstraZeneca AB

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.